Table 2. Transplant characteristics and... | American Society of Hematology

Table 2.

Transplant characteristics and outcomes

	Patient
	1	2	3	4	5	6
HLA matching^*	5 of 8	6 of 8	7 of 10	9 of 10	7 of 10	7 of 10
Total nucleated cell dose (×10⁷/kg)	12.4	9.1	41.8	49.9	31.7	33.1
Days to neutrophil engraftment†	24	15	13	11	12	14
Days to platelet engraftment†	54	63	26	42	17	49
First post-HCT chimerism (% donor)‡	98 WB 98 CD3 98 CD15	96 WB 97 CD3 96 CD15	98 WB 98 CD3 98 CD15	95 WB	98 WB 97 CD3 98 CD15	100 WB 100 CD3 100 CD15
Most recent HCT chimerism (% donor)‡	$>$ 98 WB	$>$ 98 WB	92 WB 99 CD3 87 CD33	$>$ 95 WB	58 WB 57 CD3 43 CD33	83 WB
Psychosine (in nmol/L) at 1 y§	12	17	12	19	13.2	3.6
Acute GVHD, maximum grade (organs involved)	(Possible mild upper gut)			2 (skin)	3 (skin, gut)
Feeding intolerance post-HCT	Yes	Yes	Yes	Yes	Yes	Yes
Transplant complications\|\|		CMV viremia, renal insufficiency, pericardial effusion, AIHA	AIHA		Colonic perforation related to colonoscopy	VOD, renal insufficiency, bacterial infection

	Patient
	1	2	3	4	5	6
HLA matching^*	5 of 8	6 of 8	7 of 10	9 of 10	7 of 10	7 of 10
Total nucleated cell dose (×10⁷/kg)	12.4	9.1	41.8	49.9	31.7	33.1
Days to neutrophil engraftment†	24	15	13	11	12	14
Days to platelet engraftment†	54	63	26	42	17	49
First post-HCT chimerism (% donor)‡	98 WB 98 CD3 98 CD15	96 WB 97 CD3 96 CD15	98 WB 98 CD3 98 CD15	95 WB	98 WB 97 CD3 98 CD15	100 WB 100 CD3 100 CD15
Most recent HCT chimerism (% donor)‡	$>$ 98 WB	$>$ 98 WB	92 WB 99 CD3 87 CD33	$>$ 95 WB	58 WB 57 CD3 43 CD33	83 WB
Psychosine (in nmol/L) at 1 y§	12	17	12	19	13.2	3.6
Acute GVHD, maximum grade (organs involved)	(Possible mild upper gut)			2 (skin)	3 (skin, gut)
Feeding intolerance post-HCT	Yes	Yes	Yes	Yes	Yes	Yes
Transplant complications\|\|		CMV viremia, renal insufficiency, pericardial effusion, AIHA	AIHA		Colonic perforation related to colonoscopy	VOD, renal insufficiency, bacterial infection

AIHA, autoimmune hemolytic anemia; CD3, percentage of CD3⁺ cells; CD15, percentage of CD15⁺ cells; CMV, cytomegalovirus; GVHD, graft versus host disease; HLA, human leukocyte antigen; P, patient; VOD, veno-occlusive disease; WB, whole blood.

HLA loci considered in matching included A, B, C, DRβ1 if matching 8 loci and DQ if matching at 10 loci.

†

Defined as the first of 3 consecutive post-HCT days with an absolute neutrophil count ≥500 cells/mm³ or the first of 3 consecutive days with an untransfused platelet count ≥20 000/mm³.

‡

First postengraftment restriction fragment length polymorphism performed around day +30 post-HCT.

Psychosine levels measured on dried blood spot (normal <2 nmol/L, P1, P2, and P5) or whole blood samples (normal <10 nmol/L; P3, P4, P6).

Complications were mild and self-resolved (renal insufficiency [P2 and P6]) or required treatment and resolved (CMV viremia [P2], pericardial effusion [P2], AIHA [P3], perforation [P5], VOD [P6], bacterial infection [P6]).

View Large

This Feature Is Available To Subscribers Only